Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia

Respiratory Care

Volumn 59, Issue 4, 2014, Pages 564-573

  Ugajin, Motoi ^a   Yamaki, Kenichi ^a   Hirasawa, Natsuko ^a   Yagi, Takeo ^a  

^a Ichinomiya Nishi Hospital   (Japan)

Author keywords

Albumin; Blood urea nitrogen; Community acquired pneumonia; Mortality; Semi quantitative procalcitonin test; Severity

Indexed keywords

BETA LACTAM ANTIBIOTIC; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLINDAMYCIN; GLUTAMATE DEHYDROGENASE; HYPERTENSIVE AGENT; MACROLIDE; PROCALCITONIN; QUINOLONE DERIVATIVE; SERUM ALBUMIN; TETRACYCLINE DERIVATIVE; UREASE; CALCITONIN; PROTEIN PRECURSOR;

AGED; ARTICLE; BLOOD PRESSURE; BREATHING RATE; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION; CONTROLLED STUDY; DEHYDRATION; DISEASE SEVERITY; DISGNOSTIC TEST ACCURACY STUDY; FEMALE; HEMATOCRIT; HUMAN; IMMUNOASSAY; INTENSIVE CARE; LEGIONELLA PNEUMOPHILA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OXYGEN DESATURATION; PNEUMONIA SEVERITY INDEX; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY FAILURE; SCORING SYSTEM; SEMI QUANTITATIVE PROCALCITONIN TEST; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; UREA NITROGEN BLOOD LEVEL; VERY ELDERLY; BACTERIAL PNEUMONIA; BLOOD; COMMUNITY ACQUIRED INFECTION; EPIDEMIOLOGY; INTENSIVE CARE UNIT; JAPAN; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; UTILIZATION;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD UREA NITROGEN; C-REACTIVE PROTEIN; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; INTENSIVE CARE UNITS; JAPAN; MALE; PNEUMONIA, BACTERIAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; RETROSPECTIVE STUDIES; ROC CURVE; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX;

EID: 84898735972     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.02807     Document Type: Article

References (39)

1. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community- acquired pneumonia. N Engl J Med 1997;336(4):243-250.
2. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58(5):377-382.
3. Yanagihara K, Kohno S, Matsusima T. Japanese guidelines for the management of community-acquired pneumonia. Int J Antimicrob Agents 2001;18(Suppl 1):S45-S48.
4. Rudolph JL, Zanin NM, Jones RN, Marcantonio ER, Fong TG, Yang FM, et al. Hospitalization in community-dwelling persons with Alzheimer's disease: frequency and causes. J Am Geriatr Soc 2010; 58(8):1542-1548.
5. Shah BA, Ahmed W, Dhobi GN, Shah NN, Khursheed SQ, Haq I. Validity of pneumonia severity index and CURB-65 severity scoring systems in community acquired pneumonia in an Indian setting. Indian J Chest Dis Allied Sci 2010;52(1):9-17.
6. Masiá M, Gutiérrez F, Shum C, Padilla S, Navarro JC, Flores E, Hernández I. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005;128(4):2223-2229.
7. Horie M, Ugajin M, Suzuki M, Noguchi S, Tanaka W, Yoshihara H, et al. Diagnostic and prognostic value of procalcitonin in community- acquired pneumonia. Am J Med Sci 2012;343(1):30-35.
8. Park JH, Wee JH, Choi SP, Oh SH. The value of procalcitonin level in community-acquired pneumonia in the ED. Am J Emerg Med 2012;30(7):1248-1254.
9. Kasamatsu Y, Yamaguchi T, Kawaguchi T, Tanaka N, Oka H, Nakamura T, et al. Usefulness of a semi-quantitative procalcitonin test and the A-DROP Japanese prognostic scale for predicting mortality among adults hospitalized with community-acquired pneumonia. Respirology 2012;17(2):330-336.
10. Farr BM, Sloman AJ, Fisch MJ. Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 1991; 115(6):428-436.
11. Raz R, Dyachenko P, Levy Y, Flatau E, Reichman N. A predictive model for the management of community-acquired pneumonia. Infection 2003;31(1):3-8.
12. Potgieter PD, Hammond JM. The intensive care management, mortality and prognostic indicators in severe community-acquired pneumococcal pneumonia. Intensive Care Med 1996;22(12):1301-1306.
13. Lee JH, Kim J, Kim K, Jo YH, Rhee J, Kim TY, et al. Albumin and C-reactive protein have prognostic significance in patients with community- acquired pneumonia. J Crit Care 2011;26(3):287-294.
14. Ugajin M, Yamaki K, Iwamura N, Yagi T, Asano T. Blood urea nitrogen to serum albumin ratio independently predicts mortality and severity of community-acquired pneumonia. Int J Gen Med 2012;5: 583-589.
15. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Ann Intern Med 2003; 138(1):40-44.
16. Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med 2000;26(Suppl 2):S148-S152.
17. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin- 8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001;164(3):396-402.
18. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101(6):1644-1655.
19. Giamarellos-Bourboulis EJ, Mega A, Grecka P, Scarpa N, Koratzanis G, Thomopoulos G, Giamarellou H. Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient? Intensive Care Med 2002;28(9): 1351-1356.
20. Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J 2011;37(2):384-392.
21. Krüger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum H, et al. Procalcitonin predicts patients at low risk of death from community- acquired pneumonia across all CRB-65 classes. Eur Respir J 2008;31(2):349-355.
22. Manzano S, Bailey B, Girodias JB, Cousineau J, Delvin E, Gervaix A. Comparison of procalcitonin measurement by a semi-quantitative method and an ultra-sensitive quantitative method in a pediatric emergency department. Clin Biochem 2009;42(15):1557-1560.
23. Kordek A, Podraza W, Czajka R. Reliability of semiquantitative determination of procalcitonin serum concentrations in neonates. Diagn Microbiol Infect Dis 2006;56(1):31-34.
24. Polzin A, Pletz M, Erbes R, Raffenberg M, Mauch H, Wagner S, et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 2003;21(6):939-943.
25. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, Bohuon C. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994;79(6):1605-1608.
26. Viallon A, Guyomarc'h P, Guyomarc'h S, Tardy B, Robert F, Marjollet O, et al. Decrease in serum procalcitonin levels over time during treatment of acute bacterial meningitis. Crit Care 2005;9(4): R344-350.
27. Pettilä V, Hynninen M, Takkunen O, Kuusela P, Valtonen M. Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive Care Med 2002;28(9):1220-1225.
28. Phua J, Koay ES, Lee KH. Lactate, procalcitonin, and amino-terminal pro-B-type natriuretic peptide versus cytokine measurements and clinical severity scores for prognostication in septic shock. Shock 2008;29(3):328-333.
29. Rahimkhani M, Einollahi N, Khavari Daneshvar H, Dashti N. Survey of serum procalcitonin in cirrhotic patients. Acta Med Iran 2013; 51(3):153-156.
30. Amour J, Birenbaum A, Langeron O, Le Manach Y, Bertrand M, Coriat P, et al. Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis of postoperative infection after vascular surgery. Crit Care Med 2008;36(4):1147-1154.
31. Singanayagam A, Chalmers JD, Hill AT. Severity assessment in community acquired pneumonia: a review. QJM 2009;102(6):379-388.
32. Chalmers JD, Singanayagam A, Hill AT. Predicting the need for mechanical ventilation and/or inotropic support for young adults admitted to the hospital with community-acquired pneumonia. Clin Infect Dis 2008;47(12):1571-1574.
33. Querol-Ribelles JM, Tenias JM, Grau E, Querol-Borras JM, Climent JL, Gomez E, Martinez I. Plasma D-dimer levels correlate with outcomes in patients with community-acquired pneumonia. Chest 2004;126(4):1087-1092.
34. Christ-Crain M, Stolz D, Jutla S, Couppis O, Müller C, Bingisser R, et al. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med 2007;176(9):913-920.
35. Christ-Crain M, Breidthardt T, Stolz D, Zobrist K, Bingisser R, Miedinger D, et al. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia. J Intern Med 2008; 264(2):166-176.
36. Masiá M, Papassotiriou J, Morgenthaler NG, Hernández I, Shum C, Gutiérrez F. Midregional pro-A-type natriuretic peptide and carboxy- terminal provasopressin may predict prognosis in communityacquired pneumonia. Clin Chem 2007;53(12):2193-2201.
37. Krüger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010;182(11):1426-1434.
38. Hedlund JU, Hansson LO, Ortqvist AB. Hypoalbuminemia in hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995;155(13):1438-1442.
39. Al-Shaiba R, McMillan DC, Angerson WJ, Leen E, McArdle CS, Horgan P. The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases. Br J Cancer 2004;91(2):205-207.